HalioDx designs and develops diagnostic tests in oncology utilizing the immune contexture of cancers.
HalioDx designs and develops diagnostic tests in oncology utilizing the immune contexture of cancers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 17, 2018 | Series B | €18.50M | 1 | — | — | Detail |